Zobrazeno 1 - 10
of 18
pro vyhledávání: '"R E, Hempling"'
Publikováno v:
Journal of surgical oncology. 72(1)
The safety of laparoscopic surgery in women with a family history of ovarian cancer predicted to have benign disease has not been established. The objective of this study was to evaluate the feasibility and complications of operative laparoscopy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4350d3d5661e9627d356100c8fd0a34e
https://pubmed.ncbi.nlm.nih.gov/10477869
https://pubmed.ncbi.nlm.nih.gov/10477869
Publikováno v:
Journal of surgical oncology. 70(1)
The clinical picture, response to therapy, and prognosis of women with diffuse malignant peritoneal mesotheliomas (DMPM) are ill defined. The purpose of this study is to report on the clinical picture, response to therapy, and survival of women with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9f955aebd59e35213ee3a6d3dd96999
https://pubmed.ncbi.nlm.nih.gov/9989414
https://pubmed.ncbi.nlm.nih.gov/9989414
Publikováno v:
Journal of surgical oncology. 68(3)
The incidence and significance of lymph node involvement in patients with primary peritoneal adenocarcinoma (PPA) are unknown. The aim of the current study is to report on the incidence and significance of clinically or surgically detectable lymphade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52adaed0d323e2bb1e1a4908335ea09e
https://pubmed.ncbi.nlm.nih.gov/9701204
https://pubmed.ncbi.nlm.nih.gov/9701204
Publikováno v:
European journal of gynaecological oncology. 19(3)
The hybrid capture human papillomavirus (HPV) DNA assay is offered by the manufacturer to assist clinicians with patients with ASCUS pap smear results to assess the risk factor and to potentially direct follow-up of these patients. In our practice, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8103b7d6ccb1a88b0a43afe820c53fd3
https://pubmed.ncbi.nlm.nih.gov/9641214
https://pubmed.ncbi.nlm.nih.gov/9641214
Publikováno v:
European journal of gynaecological oncology. 19(1)
This study was conduced to assess the results of paclitaxel plus cisplatin given over six months as firstline therapy in women with stage III and IV epithelial ovarian cancer with residual disease1 cm and compare it to our previous standard of cispla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::18d4790d711dd0b2fa15d2b69915f3d3
https://pubmed.ncbi.nlm.nih.gov/9476049
https://pubmed.ncbi.nlm.nih.gov/9476049
Publikováno v:
Cancer. 78(10)
This study was conducted to evaluate survival rates for patients with clear cell ovarian carcinoma who had platinum-based chemotherapy versus nonplatinum-based chemotherapy and the risk of thromboembolic complications.One hundred and eleven evaluable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2dfbb09ed7136bca27685e877dc51f9e
https://pubmed.ncbi.nlm.nih.gov/8918409
https://pubmed.ncbi.nlm.nih.gov/8918409
Publikováno v:
Cancer. 74(2)
Survival rates for patients with advanced epithelial ovarian cancer remain low despite improved chemotherapy regimens and cytoreductive surgery.One hundred thirty-six patients with Stage III or IV ovarian cancer were treated with primary cytoreductiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::353102406ef32d714dcdcab98fc560bb
https://pubmed.ncbi.nlm.nih.gov/8033045
https://pubmed.ncbi.nlm.nih.gov/8033045
Autor:
R E, Hempling
Publikováno v:
Obstetrics and gynecology clinics of North America. 21(1)
The role of tumor markers in the management of patients with epithelial ovarian cancer is expanding rapidly. Initially using heteroantisera and, most recently, monoclonal antibody-dependent assays, clinicians are equipped with new modalities that may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::190a08d0c92498b84ea6f6a44ed17488
https://pubmed.ncbi.nlm.nih.gov/8015766
https://pubmed.ncbi.nlm.nih.gov/8015766
Publikováno v:
European journal of gynaecological oncology. 15(3)
Twenty-five patients with progressive, cisplatin-resistant epithelial ovarian cancer received 5-Fluorouracil (5-FU) 500 mg/m2 days one through three and Mitomycin-C 10 mg/m2 every 28 days in a phase II trial. Myelotoxicity manifested as thrombocytope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd8418f14ac54fc45e764701f89277ba
https://pubmed.ncbi.nlm.nih.gov/7957319
https://pubmed.ncbi.nlm.nih.gov/7957319
Autor:
M. Watson, G Fortier, J Wojcicka, O. Shokek, S. Pandelidis, D Lasher, B. Kassas, R. E. Hempling, K. Mudge, D. E. Johnson, S. Yacoub, A. Shah, T. Bell, R.K. Pramanik, T. L. Bauer, R. Grim
Publikováno v:
Journal of Clinical Oncology. 29:122-122
122 Background: Partial breast irradiation (PBI) remains investigational until comparisons to whole-breast external beam radiotherapy (EBRT) confirm noninferiority. Methods: From 2004 to 2010, 103 patients at York Cancer Center (Pennsylvania) who und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d36579c1361f9c7b12cefbb5a20e2963
https://doi.org/10.1200/jco.2011.29.27_suppl.122
https://doi.org/10.1200/jco.2011.29.27_suppl.122